Novartis (NVS) said Tuesday that longer-term data from a pivotal phase 3 NATALEE trial of Kisqali as early breast cancer therapy reinforced its efficacy that extends beyond the treatment duration in combination with endocrine therapy.
Latest data showed a sustained reduction in distant recurrence of 28.5% in patients versus endocrine therapy alone, the company said. Reduced distant recurrence - known as distant disease-free survival, or DDFS - refers to decreased rate of cancer returning and spreading to other organs, it said.
The DDFS with Kisqali was observed uniformly among all pre-specified patient subgroups, including those with node-negative disease, the company said.
Novartis said the late-breaking data presented at the 2024 San Antonio Breast Cancer Symposium also showed that Kisqali's safety profile remains unchanged, with no new safety signals having been identified.
Price: 100.79, Change: -0.89, Percent Change: -0.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。